论文部分内容阅读
在美国每年诊断近1800例新的眼内原发性恶性肿瘤,此外,每年由于这一类病所致的死亡将近400例。脉络膜黑色素瘤约占所有原发性眼肿瘤的75%,而视网膜母细胞瘤约占20%。对于有用视力的病人,放射治疗往往是眼内肿瘤的首要治疗方法。遗憾的是眼内癌的放疗并不全部令人满意,在放疗后经常可见到放射性视网膜病变和局部肿瘤的复发。光凝和冷冻可用作治疗眼内肿瘤的代替或辅助疗法,但这些疗法仅对小的病变有用。显然,需要寻找治疗原发性和复发性眼内肿瘤的另外的方法。应用血卟啉衍生物(hematoporphyrin deri
Nearly 1,800 new intraocular primary malignancies are diagnosed each year in the United States and in addition nearly 400 deaths each year from this type of disease. Choroidal melanoma accounts for about 75% of all primary ocular tumors, while retinoblastoma accounts for about 20%. For patients with useful visual acuity, radiation therapy is often the primary treatment for intraocular tumors. Unfortunately, the radiotherapy of intraocular cancers is not entirely satisfactory, and radiotr retinopathy and local tumor recurrences are often seen after radiotherapy. Photocoagulation and freezing can be used as an alternative or adjuvant therapy for the treatment of intraocular tumors, but these therapies are only useful for small lesions. Obviously, there is a need to find additional ways to treat primary and recurrent intraocular tumors. Application hematoporphyrin derivative (hematoporphyrin deri